Autolus Therapeutics plc stock is up 26.53% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 2 PUTs. 100% of analysts rate it a buy.
Autolus Therapeutics plc develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trials for adult ALL. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development.